Teva, through its buyout of Cephalon, owned 60% of the rights to the stem cell therapy MPC-150-IM, but has now returned full rights back to the Australian company. The drug is in late-stage testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results